Working... Menu

Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01442987
Recruitment Status : Completed
First Posted : September 29, 2011
Last Update Posted : August 13, 2013
Information provided by (Responsible Party):
Hanmi Pharmaceutical Company Limited

Brief Summary:
The purpose of this study is to evaluate efficacy and safety of coadministered Irbesartan and Atorvastatin in patients with hypertension and hyperlipidemia.

Condition or disease Intervention/treatment Phase
Hypertension Hyperlipidemia Drug: Irbesartan/Atorvastatin A Drug: Irbesartan Drug: Atorvastatin A Drug: Placebo Drug: Irbesartan/Atorvastatin B Drug: Atorvastatin B Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 230 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Coadministered Irbesartan and Atorvastatin in Patients With Hypertension and Hyperlipidemia
Study Start Date : May 2011
Actual Primary Completion Date : April 2013
Actual Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Irbesartan/Atorvastatin A Drug: Irbesartan/Atorvastatin A
once daily, P.O. 8week
Other Name: HCP0912 A

Active Comparator: Irbesartan Drug: Irbesartan
once daily, P.O. 8week

Active Comparator: Atorvastatin A Drug: Atorvastatin A
once daily, P.O. 8week

Placebo Comparator: Placebo Drug: Placebo
once daily, P.O. 8week

Experimental: Irbesartan/Atorvastatin B Drug: Irbesartan/Atorvastatin B
once daily, P.O. 8week
Other Name: HCP0912 B

Active Comparator: Atorvastatin B Drug: Atorvastatin B
once daily, P.O. 8week

Primary Outcome Measures :
  1. Percent change from baseline to 8 week in LDL-Cholesterol [ Time Frame: baseline and 8 week ]
  2. Change from baseline to 8 week in Blood Pressure. [ Time Frame: baseline and 8 week ]

Secondary Outcome Measures :
  1. Percentage of patients reaching treatment goals according to NCEP ATP III Guideline and Blood pressure responder rate according to JNC VII Guideline. [ Time Frame: week 8 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   19 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged between 19 and 75 years
  • Signed informed consent

Exclusion Criteria:

  • At screening, SPB ≥ 180mmHg or DBP ≥ 110mmHg or LDL-C > 250mg/dL or TG ≥ 400mg/dL
  • Has a history of hypersensitivity to Angiotensin Ⅱ receptor blocker or HMG-CoA reductase inhibitor or component of this drug
  • Has a history of multi-drug allergy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01442987

Layout table for location information
Korea, Republic of
16 institutions including Seoul National University Hospital
Seoul, Korea, Republic of
Sponsors and Collaborators
Hanmi Pharmaceutical Company Limited
Layout table for investigator information
Principal Investigator: Byeong Hee Oh, M.D Seoul National University Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Hanmi Pharmaceutical Company Limited Identifier: NCT01442987     History of Changes
Other Study ID Numbers: HM-IBAT-301
First Posted: September 29, 2011    Key Record Dates
Last Update Posted: August 13, 2013
Last Verified: August 2013

Keywords provided by Hanmi Pharmaceutical Company Limited:

Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists